Find and Pitch Jounalists, Get Your Story Covered

Tags: leadership pharma Research & Development research-development biotech

	Profile	Recent Articles on Subject
1	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about GSK leaving BIO, an AbbVie schizophrenia drug failing, and more - 3 days ago STAT+: Up and down the ladder: The latest comings and goings - 6 days ago STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 8 days ago STAT+: Up and down the ladder: The latest comings and goings - 13 days ago STAT+: Pharmalittle: We’re reading about pharma risks in China, mitigating shortages, and more - 13 days ago STAT+: Up and down the ladder: The latest comings and goings - 20 days ago STAT+: Up and down the ladder: The latest comings and goings - 27 days ago STAT+: Up and down the ladder: The latest comings and goings - 2 months ago STAT+: Up and down the ladder: The latest comings and goings - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 7 months ago STAT+: Up and down the ladder: The latest comings and goings - 7 months ago STAT+: European Parliament votes in favor of updated pharma legislation, prompting mixed reactions - 7 months ago STAT+: Pharmalittle: We’re reading about Biocon eyeing weight loss drugs, Sanofi layoffs, and more - 7 months ago STAT+: Pharmalittle: We’re reading about Amgen suing Colorado over drug price caps, abortion pills, and more - 8 months ago STAT+: Up and down the ladder: The latest comings and goings - 8 months ago STAT+: Pharmalittle: We’re reading about BIO cutting ties with WuXi, EU pharma rules, and more - 8 months ago STAT+: Pharmalittle: We’re reading about a tossed PhRMA lawsuit, secrecy clauses, and more - 9 months ago STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news - 10 months ago STAT+: Pharmalittle: FDA approvals rebound, abortion pill orders rise, and more news - 11 months ago STAT+: Pharmalittle: Pfizer is leaving the BIO trade group; CVS drug-pricing plan may not lower costs for consumers - 11 months ago STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax - about 1 year ago STAT+: Pharmalittle: Life sciences deals on track to hit lowest point since 2017; EU regulators order Illumina to divest Grail - about 1 year ago
2	Lizzy Lawrence STAT News Medical devices reporter at STATnews. Loves news tips. medical reportingnews	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - 6 days ago
3	John Wilkerson STAT News STAT Washington correspondent. Healthcare Journalism	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - 6 days ago
4	Sarah Owermohle STAT News Health reporter @STATNews. Covers Biden's agenda. Washington, District of Columbia health policyjournalism	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - 6 days ago
5	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 8 days ago Listen: Pharma goes to Washington, Alnylam’s future, & Gilead’s dealmaking - 9 months ago
6	Matthew Herper STAT News Writes at STAT. Biology's century. Undisclosed biologydatajournalism	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 8 days ago
7	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 8 days ago
8	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 8 days ago
9	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	Pharma takes aim at a wily foe — the Epstein-Barr virus - 10 days ago 2024 PharmaVoice 100s: Trailblazers - 29 days ago Who’s winning in biotech’s tight market? - 2 months ago What 3 layoff stories reveal about pharma’s troubles - 2 months ago What pharma has learned from AI - 3 months ago Pharma’s R&D gamble: picking pipeline winners in a risky field - 5 months ago Where competition is heating up in pharma - 6 months ago 3 big recent trial flops - 7 months ago The biggest questions hanging over pharma in 2024 - 10 months ago Pharma execs sound off on trends and policies they’re tracking in 2024 - 10 months ago PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials - 10 months ago 10 of our most read articles in 2023 - 11 months ago PharmaVoice 100s: Entrepreneurs - about 1 year ago PharmaVoice 100s: Clinical trial gurus - about 1 year ago 3 recent FDA adcomm rejections — and why they matter - about 1 year ago
10	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	3 FDA approval dates to watch in the year’s final push - 2 months ago Pharma’s concerns pile up months after Supreme Court’s landmark Chevron decision - 3 months ago Read to lead: 6 books pharma execs swear by - 4 months ago 4 offbeat biotechs making a splash in the life sciences - 7 months ago COVID vaccine giants Moderna and Pfizer employ divergent tactics for the next chapter - 8 months ago Could pharma’s legal attack on the IRA succeed in killing price negotiations? - 8 months ago

Journalists covering BioPharma, Legal, Pharma